Comparative Pharmacology
Head-to-head clinical analysis: LIGNOSPAN FORTE versus LIGNOSPAN STANDARD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIGNOSPAN FORTE versus LIGNOSPAN STANDARD.
LIGNOSPAN FORTE vs LIGNOSPAN STANDARD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lidocaine and prilocaine stabilize neuronal membranes by inhibiting sodium ion influx, thereby blocking initiation and conduction of nerve impulses.
Lidocaine, the active ingredient, inhibits voltage-gated sodium channels, blocking the initiation and conduction of nerve impulses, leading to local anesthesia.
Adults: 2% lidocaine with 1:100,000 epinephrine, max 7 mg/kg lidocaine (500 mg) without epinephrine or 4.5 mg/kg (300 mg) with epinephrine; for dental infiltration or nerve block, 1-2 mL per site.
2% lidocaine with 1:100,000 epinephrine: 1-5 mL (20-100 mg lidocaine) locally infiltrated; max 7 mg/kg lidocaine (up to 500 mg) per procedure. For nerve block: 1-30 mL depending on site. Epinephrine max 0.2 mg (20 mL of 1:100,000 solution) in healthy adults.
None Documented
None Documented
Terminal elimination half-life of lidocaine: 1.5–2 hours; in hepatic impairment or heart failure, may extend to >4 hours. For the vasoconstrictor (epinephrine), half-life is approximately 2 minutes due to rapid uptake and metabolism.
Terminal elimination half-life is approximately 1.5–2 hours in adults. Prolonged in hepatic impairment or heart failure.
Renal excretion of metabolites (predominantly 4-hydroxy-2,6-xylidine and other conjugates): ~90%; biliary/fecal: <10% as unchanged drug.
Primarily hepatic metabolism; <10% excreted unchanged in urine. Biliary/fecal excretion is minimal.
Category C
Category C
Local Anesthetic with Vasoconstrictor
Local Anesthetic with Vasoconstrictor